An 245 Patienten erfolgte eine retrospektive Sudie Bezug nehmend auf die Morbidität und das lokalrezidivfreie Überleben bei Patienten mit malignem Melanom, die entweder eine limitierte oder eine erweiterte axilläre oder inguinale Lymphadenektomie erhielten.
Nach Wissen der Autoren ist vorliegende Studie die erste ihrer Art, die aufzeigt, dass die Durchführung einer erweiterten Lymphadenektomie zu keiner erhöhten Morbidität führt.
Bei Patienten mit einem positiven Lymphknotenstatus verbessert die erweiterte Lymphadenektomie das lokalrezidivfreie Überleben.
Daher stellt die erweiterte Lymphadenektomie ein mögliches Qualitätsmerkmal der axillären und inguinalen Lymphadenektomie in der Therapie des malignen Melanoms dar. / Background: Although the number of excised lymph nodes during lymph node dissection (LND) is an independent predictor of melanoma-specific survival in melanoma patients, current guidelines do not set a concrete cut-off limit for the number of lymph nodes to be resected during LND. Here we investigate if extended LND (ext-LND) has an impact on surgical morbidity and oncological outcome in melanoma patients.
Methods: As many as 245 melanoma patients receiving axillary or inguinal LND in curative intention were investigated retrospectively. Ext-LND was defined as axillary LND with 20 or more resected lymph nodes and inguinal LND with 10 or more resected lymph nodes. Surgical morbidity (lymphatic fistulas, wound infections, severe bleeding, neurological affection) and local recurrence-free survival were also investigated.
Results: Ext-LND did not lead to increased surgical morbidity in the overall study collective. After ext-LND, 55.4% of the patients experienced one of the investigated complications compared to 46.2% in the limited LND group (p=0.2113). There was no difference in the occurrence of lymphatic fistula, wound infection, severe bleeding, or neurological affection. In addition, patients with positive lymph node status showed improved local recurrence-free survival following ext-LND (p=0.0425).
Conclusion: Ext-LND can be considered a quality marker of LND in melanoma patients.
| Identifer | oai:union.ndltd.org:uni-wuerzburg.de/oai:opus.bibliothek.uni-wuerzburg.de:21153 |
| Date | January 2020 |
| Creators | Mathe, Katrin |
| Source Sets | University of Würzburg |
| Language | deu |
| Detected Language | English |
| Type | doctoralthesis, doc-type:doctoralThesis |
| Format | application/pdf |
| Rights | https://opus.bibliothek.uni-wuerzburg.de/doku/lic_mit_pod.php, info:eu-repo/semantics/openAccess |
Page generated in 0.0022 seconds